These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2174840)

  • 1. Continuous, hyperfractionated, accelerated radiotherapy (CHART) in non-small cell carcinoma of the bronchus.
    Saunders MI; Dische S
    Int J Radiat Oncol Biol Phys; 1990 Nov; 19(5):1211-5. PubMed ID: 2174840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601).
    Tsuchiya S; Ohe Y; Sugiura T; Fuwa N; Kitamoto Y; Mori K; Kobayashi H; Nakata K; Sawa T; Hirai K; Etoh T; Saka H; Saito A; Fukuda H; Ishizuka N; Saijo N;
    Jpn J Clin Oncol; 2001 Oct; 31(10):488-94. PubMed ID: 11696618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee.
    Saunders M; Dische S; Barrett A; Harvey A; Griffiths G; Palmar M
    Radiother Oncol; 1999 Aug; 52(2):137-48. PubMed ID: 10577699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee.
    Saunders M; Dische S; Barrett A; Harvey A; Gibson D; Parmar M
    Lancet; 1997 Jul; 350(9072):161-5. PubMed ID: 9250182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fractionation and dose in thoracic radiotherapy.
    Saunders MI
    Lung Cancer; 1994 Mar; 10 Suppl 1():S245-52. PubMed ID: 8087516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is control of the primary tumour worthwhile in non-oat cell carcinoma of the bronchus?
    Saunders MI
    Clin Oncol (R Coll Radiol); 1991 Jul; 3(4):185-8. PubMed ID: 1657111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [CHARTWEL-Bronchus (ARO 97-1): a randomized multicenter trial to compare conventional fractionated radiotherapy with CHARTWEL radiotherapy in inoperable non-small-call bronchial carcinoma].
    Baumann M; Herrmann T; Matthiessen W; Koch R; Strelocke K; Paul U
    Strahlenther Onkol; 1997 Dec; 173(12):663-7. PubMed ID: 9454350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II study of treatment of locally advanced (T3/T4) non-oat cell lung cancer with concomitant boost radiotherapy by the Radiation Therapy Oncology Group (RTOG 83-12): long-term results.
    Graham MV; Pajak TE; Herskovic AM; Emami B; Perez CA
    Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):819-25. PubMed ID: 7860394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accelerated hyperfractionation in patients with non-small cell bronchogenic cancers as a cost-effective and user- and patient-friendly schedule.
    Herskovic A; Fisher J; Orton B; Lee CK; Chang JH; Sandhu T; Prysby D; Scott C
    Cancer Invest; 2000; 18(6):537-43. PubMed ID: 10923102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Escalated hyperfractionated accelerated radiation therapy for locally advanced non-small cell lung cancer: a clinical phase II trial.
    Chen GY; Jiang GL; Qian H; Wang LJ; Yang HJ; Fu XL; Wu KL; Zang Z; Zhao S
    Radiother Oncol; 2004 May; 71(2):157-62. PubMed ID: 15110448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life assessment in advanced non-small-cell lung cancer patients undergoing an accelerated radiotherapy regimen: report of ECOG study 4593. Eastern Cooperative Oncology Group.
    Auchter RM; Scholtens D; Adak S; Wagner H; Cella DF; Mehta MP
    Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1199-206. PubMed ID: 11483329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase III study of accelerated radiotherapy with and without carboplatin in nonsmall cell lung cancer: an interim toxicity analysis of the first 100 patients.
    Ball D; Bishop J; Smith J; Crennan E; O'Brien P; Davis S; Ryan G; Joseph D; Walker Q
    Int J Radiat Oncol Biol Phys; 1995 Jan; 31(2):267-72. PubMed ID: 7836079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial experience with a practical hyperfractionated accelerated radiotherapy regimen.
    Herskovic A; Orton C; Seyedsadr M; Lattin P; Kraut M; Han I; Han S; Ahmad K; Holt J
    Int J Radiat Oncol Biol Phys; 1991 Oct; 21(5):1275-81. PubMed ID: 1657843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer: a phase I study.
    Frasci G; Comella P; Scoppa G; Guida C; Gravina A; Fiore F; Casaretti R; Daponte A; Parziale A; Comella G
    J Clin Oncol; 1997 Apr; 15(4):1409-17. PubMed ID: 9193333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment-related acute esophagitis for patients with locoregionally advanced non-small cell lung cancer treated with involved-field radiotherapy and concurrent chemotherapy.
    Bar-Ad V; Leiby B; Witek M; Xiao Y; Cui Y; Dai Y; Cao J; Axelrod R; Campling B; Both S; Werner-Wasik M
    Am J Clin Oncol; 2014 Oct; 37(5):433-7. PubMed ID: 23388558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total atelectasis of the lung secondary to malignant airway obstruction. Response to radiation therapy.
    Reddy SP; Marks JE
    Am J Clin Oncol; 1990 Oct; 13(5):394-400. PubMed ID: 2171317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neoadjuvant radiochemotherapy in locally advanced non-small cell bronchial carcinoma. Initial results of a prospective multicenter study].
    Wagner W; von Eiff M; Klinke F; Micke O; Rübe C; Willich N
    Strahlenther Onkol; 1995 Jul; 171(7):390-7. PubMed ID: 7631260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The radiotherapy of inoperable non-small-cell bronchial carcinoma. A retrospective analysis of 427 cases].
    Würschmidt F; Bünemann H; Bünemann C; Beck-Bornholdt HP; Heilmann HP
    Strahlenther Onkol; 1994 May; 170(5):302-4. PubMed ID: 8197553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid).
    Zehentmayr F; Söhn M; Exeli AK; Wurstbauer K; Tröller A; Deutschmann H; Fastner G; Fussl C; Steininger P; Kranzinger M; Belka C; Studnicka M; Sedlmayer F
    Radiat Oncol; 2015 May; 10():121. PubMed ID: 26018527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Postoperative radiotherapy in curatively resected non-small-cell bronchial carcinoma].
    Klages HT; Stuschke M
    Strahlenther Onkol; 1999 Mar; 175(3):134-6; discussion 136-7. PubMed ID: 10093616
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.